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Background: Congenital and inherited myopathies in dogs are faithful models of human muscle diseases and are
being recognized with increasing frequency. In fact, canine models of dystrophin deficient muscular dystrophy and
X-linked myotubular myopathy are of tremendous value in the translation of new and promising therapies for the
treatment of these diseases. We have recently identified a family of Australian Rottweilers in which male puppies
were clinically affected with severe muscle weakness and atrophy that resulted in early euthanasia or death. X-linked
myotubular myopathy was suspected based on the early and severe clinical presentation and histopathological
changes within muscle biopsies. The aim of this study was to determine the genetic basis for myopathy in these dogs
and compare and contrast the clinical presentation, histopathology, ultrastructure, and mutation in this family of
Rottweiler dogs with the previously described myotubular myopathy in Labrador retrievers.
Results: Histopathology, histochemistry, and ultrastructural examination of muscle biopsies from affected Rottweiler
puppies were consistent with an X-linked myotubular myopathy. An unusual finding that differed from the previously
reported Labradors and similar human cases was the presence of excessive autophagy and prominent autophagic
vacuoles. Molecular investigations confirmed a missense mutation in exon 11 of MTM1 that was predicted to result in
a non-functional phosphatase activity. Although the clinical presentations and histopathology were similar, the MTM1
p.(Q384P) mutation is different from the p.(N155K) mutation in exon 7 affecting Labrador retrievers with X-linked
myotubular myopathy.
Conclusions: Here we describe a second pathogenic mutation in MTM1 causing X-linked myotubular myopathy in
dogs. Our findings suggest a variety of MTM1 mutations in dogs as seen in human patients. The number of MTM1
mutations resulting in similar severe and progressive clinical myopathy and histopathological changes are likely to
increase as canine myopathies are further characterized.
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The centronuclear myopathies (CNMs) are a group of
pathologically defined disorders that characteristically
have a high proportion of small myofibers with centrally
placed nuclei [1-3]. Classical centronuclear myopathies
in humans have been associated with dominant mutations
in the large GTPase DNM2 gene [4] while recessive cases* Correspondence: beggs@enders.tch.harvard.edu
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unless otherwise stated.may be due to mutations of amphiphysin 2, encoded by
BIN1 [5], and of the ryanodine receptor (RyR1) gene,
RYR1 [6]. An important, well-defined sub-group of CNMs
is X-linked myotubular myopathy (XLMTM) associated
with mutations in theMTM1 gene [7]. The protein product,
myotubularin, is a ubiquitously expressed 603 amino acid
phosphoinositide phosphatase that is essential in a wide
variety of cellular signaling pathways governing diverse
cellular functions including apoptosis and vesicle trafficking
[8]. In skeletal muscle, myotubularin is localized at the
terminal cisternae of the sarcoplasmic reticulum (SR) wherel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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membranes at the triads [9]. Abnormal membrane
tubulation in myotubularin-deficient muscle leads to
altered T-tubule and triad morphology and defective
excitation contraction coupling, which is thought to
play a major role in the initial pathophysiological
events leading to weakness [10,11]. Clinical onset of
XLMTM is at or near birth with males born with
severe generalized hypotonia and weakness with respiratory
insufficiency [12]. Affected infants are typically areflexic
and hypotonic with little or no anti-gravity movements.
The condition is not dystrophic as myofibers remain largely
intact and serum creatine kinase (CK) activities are within
the reference range or only mildly elevated.
In veterinary medicine, the first mutation associated
with classical CNM was identified in young Labrador
retrievers. A widely distributed exonic SINE insertion in
the PTPLA gene segregated with autosomal recessive
CNM in these dogs [13]. Mutations in the PTPLA gene
have not been reported to date in human cases of CNM,
however, mutation in the BIN1 exon 11 acceptor splice
site was recently shown to be the cause of a rapidly
progressive and fatal centronuclear myopathy in both a
consanguineous human family and in young Great Dane
dogs with a progressive CNM [14]. While specific mutations
have not yet been identified, CNM has also been reported
in a family of young Manchester Terriers (G.D. Shelton,
unpublished observations), in a young Border Collie [15],
and in an Arabian foal [16].
In 2008, a form of CNM resembling XLMTM was
described in a family of Labrador Retrievers from
Canada [17]. Molecular investigation confirmed that these
dogs indeed did have anMTM1 mutation and represented
a faithful model of human XLMTM [18]. Male puppies
from two kindreds were presented for evaluation of
progressive weakness and muscle atrophy beginning
in the first few months of life. Pathological changes
in muscle biopsies were consistent with a myotubular
myopathy and a missense mutation, p.(N155K), was
identified in exon 7 of canine MTM1. Here we de-
scribe, compare, and contrast the clinical presentation,
histopathology, muscle ultrastructure, and a second inde-




All dogs reported in this communication were privately
owned pets receiving clinical veterinary care and no
experimental procedures were carried out on live animals.
All research on tissue biopsies and blood samples was
performed on specimens collected and submitted for clin-
ical diagnostic purposes and the owners and breeders
were informed and gave consent to study tissues forthe welfare of the breed. Four male puppies, aged 8
to 13 weeks, were presented to the Small Animal
Specialist Hospital, North Ryde, Australia (GC and ST) for
evaluation of progressive muscle weakness. The affected
puppies were from two different litters with the same dam
and sire (Figure 1). The sire of both litters had sired two
other litters from different dams with no reported
abnormalities in the offspring. DNA for genetic testing
was collected from all four affected puppies and 10
unaffected first-degree relatives. Additional unaffected
control samples were obtained from The Rottweiler
Blood Bank, The University of Manchester, Manchester,
UK, The Faculty of Veterinary Science, University of
Sydney, Australia, and the Animal Specialist Hospital,
North Ryde, Australia. None of the dogs in the unaffected
control groups showed clinical signs of a neuromuscular
disease.
Histopathology, histochemistry, and immunofluorescence
staining
Immediately after collection, muscle biopsy specimens
were either wrapped in a saline-dampened gauze sponge
and immediately refrigerated or immersion-fixed in 10%
neutral buffered formalin. All specimens were shipped by
a courier service under refrigeration to the Comparative
Neuromuscular Laboratory, University of California San
Diego. Immediately on receipt, unfixed specimens were
flash-frozen in isopentane precooled in liquid nitrogen
and stored at -80°C until further processing. Control mus-
cles were all histologically normal specimens from the fro-
zen tissue archive of the Shelton laboratory. Cryosections
(8 μm) were cut and processed by a standard panel of
histochemical stains and reactions [19]. Mouse monoclonal
antibodies against slow (1:10, NCL-MHCs, Novocastra,
Newcastle, England) and fast (1:10, NCL-MHCf, Novocastra)
myosin heavy chains were used for fiber typing. Peroxidase
substrate kits (DAB, Vector SK-4100, Vector Laboratories,
Burlingame, CA, USA) and Vector red substrate kits (Vector,
SK-5100) were used for color development according to
package instructions.
Additional cryosections (8 μm) were cut and processed
by indirect immunofluorescence. Sections were fixed in
chilled acetone for 5 min, then incubated with a rabbit
polyclonal antibody against the T-tubule marker, dihy-
dropyridine receptor (DHPR), DHPRα1 (ab58552, 1:100
dilution, Abcam, Cambridge, UK) and a mouse mono-
clonal antibody against the SR marker, RyR1 (ab2827,
1:100 dilution; Abcam, Cambridge, UK). Rabbit poly-
clonal antibodies against LC3 N terminal (1:100,
Abgent AP1802a, Abgent, San Diego, CA, USA) and
ubiquitin (1:250, Dako 2015-02, Dako Denmark A/S,
Glostrup, Denmark) were used as markers for au-
tophagy. Details of further processing are as previously
described [18].
Figure 1 Clinical presentations and family history of affected dogs. Photographs of the healthy dam II-2 (A), sire II-3 (B), and two affected
male littermates III-12 (C) and III-13 (D) at 12 weeks of age. (E) Pedigree of the two affected Rottweiler litters with male puppies that presented
with progressive muscle weakness. The 15 members whose DNA was available for analysis are indicated by an asterisk. Squares =males,
circles = females, SB = still born. Filled symbols indicate clinically affected. The dot in the center of II-2 indicates her genetically confirmed
status as a carrier for the MTM1 mutation illustrated below.
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Following collection, muscles were immersed in ice cold
5% glutaraldehyde for 4 h, cut into 2 to 3 mm3 blocks,
and fixed for an additional 2 h before post-fixation in
1% osmium tetroxide for 1 h. The samples were
dehydrated in increasing ethanol concentrations and
finally propylene oxide, and then embedded in ara-
ldite resin. Thick sections (1 μm) were prepared and
examined by light microscopy after staining with
toluidine blue-basic fuchsin. Ultra-thin sections (60 to
65 nm) were cut and collected on 100 or 200 square
mesh grids, stained with uranyl acetate and lead cit-
rate, and examined with a Zeiss 10 electron micro-
scope. For quantification of triad structures in a
representative affected dog and an age-matched con-
trol dog, longitudinal sections were evaluated at 9,900
magnification. A triad structure was defined as the
typical T-tubule density and at least one adjacent cis-
tern. The first 10 fields encountered with no artifact
were photographed and the number of triads per field
counted.DNA extraction and MTM1 gene sequencing and analysis
Genomic DNA was isolated from muscle biopsies and
EDTA anticoagulated peripheral blood by standard proce-
dures. The 15 transcribed exons, plus 81 to 278 bp of
flanking intronic sequences, of the canine MTM1 gene
were polymerase chain reaction (PCR) amplified and
Sanger sequenced using primer set 2 as described [18].
The canine MTM1 c.1151A > C variant was screened for
in relatives of the proband and unaffected control popula-
tions using a Custom TaqMan® SNP Genotyping Assay
(Life Technologies custom assay AH89RBZ, Thermo
Fisher Scientific, Waltham, MA USA) on an ABI 7300 real
time PCR platform (Thermo Fisher Scientific). Canine
DNA and protein sequence variants are specified relative
to reference sequences XM_850116.3 and XP_855209.1
where cDNA numbering is based on designating the first
‘A’ of the initiating methionine as position 1.
Variant interpretation and mutational modeling
Potential pathogenic consequences of theMTM1 c.1151A >
C variant were assessed using SIFT (http://sift.jcvi.org/) [20],
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[21], and SuSPect (http://www.sbg.bio.ic.ac.uk/suspect/) [22]
and effects on protein structure were modeled using Phyre2
(http://www.sbg.bio.ic.ac.uk/phyre2/) [23] and visualized
using Jmol, an open-source JAVA viewer for chemical
structures in 3D (http://www.jmol.org/). Amino acid
alignments were performed using the ClustalW algorithm
in MacVector version 13.04 (MacVector Inc., Cary NC,
USA), using the following reference sequences for com-
parison. For myotubularins: human (Homo sapiens),
NP_000243.1; monkey (Macaca mulatta), NP_001248647;
dog (Canis familiaris), XP_005641991; cow (Bos taurus),
NP_001193354; chicken (Gallus gallus), XP_004940916;
xenopus (Xenopus tropicalis), AAH94184.1; zebra fish
(Danio rerio), NP_001032773.1; drosophila (Drosophila
melanogaster), AAF52327.1. For myotubularin-related
proteins: MTM1, NP_000243.1; MTMR1, NP_003819.1;
MTMR2, Q13614.4; MTMR3, CAG30411.1; MTMR4,
NP_004678.3; MTMR5, O95248.3; MTMR6, NP_004676.3;
MTMR7, EAW63816.1; MTMR8, Q96EF0.1; MTMR9,
Q96QG7.1; MTMR10, Q9NXD2.3; MTMR11, A4FU01.2;
MTMR12, Q9C0I1.2;MTMR13, Q86WG5.1.
Results
Severe and progressive myopathy in related litters of
Rottweiler puppies
A 13-week-old male Rottweiler (III-2 from Figure 1)
from a litter of 10 puppies (6 females and 4 males) was
referred for progressive weakness. Two pups from this
first litter were previously lost; the first was a female that
died within a few weeks of birth (unknown cause), and
the second a male pup (III-1) euthanized by the attending
veterinarian at 9 weeks of age for an initial alteration in
facial expression and exercise intolerance progressing to
an inability to bear weight. In the affected pup evaluated
(III-2), clinical signs of weakness had been apparent since
acquisition from the breeder at 8 weeks of age. Clinical
examination at referral revealed normal mentation, gener-
alized mild to moderate reduction in muscle mass without
myalgia, and profound tetraparesis with an inability to
support weight. Cervical ventroflexion occurred in sternal
recumbency. Spinal pain was absent. Hyporeflexia and
hypotonia were noted in all limbs, and were symmetrical
in severity. Sensory abnormalities were not detected.
There were no cranial nerve deficits. Conscious proprio-
ception (proprioceptive paw positioning) was intact. CK
was mildly elevated (2119 U/l, reference 0-400). Multiple
muscle and peripheral nerve biopsies were obtained via
open surgical biopsy under general anesthesia. After
sample collection, the puppy was euthanized for humani-
tarian reasons and at the owners’ request due to the severe
nature of the disease.
Subsequently, three male Rottweiler puppies (Figure 1E,
puppies III-12, 13, and 14) were presented with a historyof rapidly progressive generalized weakness and poor
muscle development. The puppies were from a second
litter of eight surviving puppies (6 male and 2 female, 1
additional male stillborn) produced after the second
mating of the dam and sire of puppy III-2 (Figure 1E).
Two of the affected puppies (III-12 and III-13) were pre-
sented for evaluation at 11 weeks of age. Both were
regarded as normal with respect to their littermates in
activity level and muscle development until 7 weeks of age
when the owner noted both puppies showed difficulty in
holding their heads up and tired easily. The puppies
remained bright, alert, and normally responsive, were keen
to play with their littermates but were increasingly unable
to do so. Muscle development was poor compared to their
littermates despite comparable size, a normal appetite,
and food intake. Weakness was exacerbated by any stress
and cold. The third puppy (III-14) was regarded as normal
until 9 weeks of age and was reported to be less active at
11 weeks of age. This puppy presented 2 weeks after his
littermates (at 13 weeks of age).
Clinical findings were similar for all three affected
puppies. All puppies were bright, friendly, and normally
responsive. Bent or crinkled vibrissae were identified at an
early age, and not apparent in the normal littermates. Poor
development or reduced muscle mass compared to normal
littermates was noted in the limb muscles, paraspinal mus-
cles, and masticatory muscles. The most severely affected
puppy (Figure 1C, puppy III-12) was unable to stand for
more than 10 s. All affected puppies had marked cervical
weakness, were unable to lift their heads when standing
(Figure 1D) and were unable to raise the head when ster-
nally recumbent after any exertion. The puppies adopted a
hunched thoracolumbar posture with a stiff limbed stance
and narrow base when standing. A stiff, short-stride gait
was evident before sitting or lying down. In a recumbent
position the puppies would follow the activities of other
puppies or people with their eyes rather than moving their
head or neck. When ambulatory no evidence of ataxia or
proprioceptive deficit was evident. Voluntary motor move-
ment was present in all limbs and limb positioning appro-
priate, but all showed reduced muscle strength. When
standing or encouraged to walk the respiratory rate of all
the affected puppies would increase, they would pant and
the heart rate would increase significantly (>200 bpm).
Postural reactions including proprioceptive paw
positioning were normal if the puppies’ weight was
supported. Patellar reflexes were absent in the two
most severely affected puppies (Figure 1E, puppies
III-12 and III-13) and reduced in the third affected
puppy (III-14). Flexion reflexes were present in all
four limbs in all puppies but weak in puppies III-12
and III-13. Cranial nerve examination was normal in all
three puppies. CK was normal or very mildly increased
(104, 348, 277 U/L; reference 0 to 200).
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signs, and diagnosis of myopathy in a related dog, all three
puppies were euthanized at 11 weeks of age (III-12),
12 weeks of age (III-13), and 13 weeks of age (III-14),
respectively. Skeletal and cardiac muscle and blood samples
were collected at necropsy for histology, immunohisto-
chemistry, and genetic analysis.
Histopathology, histochemistry, and
immunohistochemical findings suggest affected puppies
have a form of centronuclear myopathy with excessive
autophagy
Cryosections from the triceps, extensor carpi radialis,
tensor fascia lata, cranial tibial, and biceps femoris muscles
were evaluated from puppy III-2 (Figure 2). There was a
marked variability in myofiber size in all muscles
examined with fiber diameters in the range of 12 to
60 μm (Figure 2A). Normal canine biceps femoris
contains 41% type 1, 58% type 2, and 1% type 2C
fibers [24]. Biceps femoris from the affected dogs
displayed type 1 fiber predominance (73% type 1 fibers and
27% type 2 fibers), which was evident by antibody staining
for fast and slow myosin heavy chains (Figure 2B). Most
type 1 fibers were hypotrophic with prominent centralFigure 2 Pathological findings in skeletal muscle from an
affected puppy are suggestive of a diagnosis of XLMTM or
other form of CNM. Cryosections of the biceps femoris muscle
from the affected puppy III-2 were evaluated with a standard panel
of histochemical stains and reactions. Marked variability in myofiber
size was noted (A) with numerous hypotrophic fibers containing
central nuclei. Most hypotrophic fibers were of type 1 as determined
by staining with antibodies against slow (brown stain, type 1 fibers)
and fast (pink stain, type 2 fibers) myosin heavy chains (B). Dense
central and subsarcolemmal deposits were noted with the oxidative
reactions SDH (C) and COX (D).nuclei. The hypotrophic fibers contained central accumula-
tions and subsarcolemmal rings, the so-called ‘necklace
fibers’, that stained dark blue with the oxidative reactions
nicotinamide adenine dinucleotide - tetrazolium reductase
(not shown), succinate dehydrogenase (SDH, Figure 2C)
and cytochrome C oxidase (COX, Figure 2D). Necrotic
fibers were rare. No abnormalities were detected in the
radial, femoral, and sciatic nerve sections, and gross and
microscopic examination of the hearts from several affected
dogs revealed no evidence of cardiomyopathy or other
recognizable lesions. Based on these pathological changes, a
congenital myopathy including centronuclear myopathy or
myotubular myopathy was diagnosed. Cryosections were
also evaluated from the affected male puppies III-12 and
III-14 with similar morphologic findings.
Immunofluorescence staining of muscle cryosections
from affected puppies, using antibodies against markers
for T-tubules (DHPRα1) and SR (RyR1), revealed an
abnormal localization of both structures compared to
control muscle (Figure 3). T-tubules and surrounding
SR were concentrated in irregular densities within numer-
ous myofibers, but not in the control muscle (Figure 3A).
Antibodies against LC3 and ubiquitin, markers for
autophagy, showed prominent dense staining in most
myofibers from the affected puppies but not in control
muscle (Figure 3B).
Abnormal triads, autophagic vacuoles, and mitochondrial
accumulations were found in affected muscles from
Rotweillers with XLMTM
Ultrastructural examinations (Figure 4) were performed
on the biceps femoris muscles of puppies III-12 and III-14.
Representative images in Figure 4 are from puppy III-12.
Normal appearing triads were not observed in the sections
from the affected puppies, while 18 to 20 triads per field
were present in the control dog sections (not shown). Large
areas of myofibrillar disarray were prominent containing
degenerating organelles, and lysosomal and tubular struc-
tures (Figure 4A). Centrally located nuclei were confirmed
(Figure 4B). Dilated tubular structures (T-tubules and SR
profiles) were present throughout the sections (Figure 4C)
and clusters of mitochondria with interspersed glycogen
granules were found (Figure 4D). Remarkably, prominent
abundant autophagic vacuoles (Figure 4E,F) containing
heterogeneous contents including small dense bodies
studded with glycogen particles, membrane fragments,
myeloid structures, and debris were noted.
Identification of a novel MTM1 mutation in affected dogs
All 15 exons and between 81 and 278 bp of flanking
intronic sequences of the canine MTM1 gene were PCR
amplified from the genomic DNA of one of the affected
puppies and subjected to Sanger sequencing. The puppy’s
MTM1 coding sequence completely matched the published
Figure 3 Abnormal staining patterns for triad proteins and markers of autophagy in skeletal muscles from affected dogs. (A)
Immunofluorescence staining of cryosections from the biceps femoris muscles of Rottweiler puppies affected with XLMTM (puppies III-12 and
III-14). Irregular staining patterns were noted in affected puppies using antibodies against DHPRα1 (T-tubule marker) and RyR1 (SR marker)
compared to control muscle. (B) Compared to control muscle, dense and irregular staining patterns were also noted following staining with
the autophagy markers LC3 and ubiquitin.
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single base substitution of C for A in exon 11 at position
1151 on the coding portion of the cDNA, designated
MTM1 c.1151A >C (Figure 5A). This variant is predicted to
introduce a non-conservative missense mutation replacing a
glutamine at position 384 with a proline, designated
p.(Q384P). Further PCR amplification and sequencing of
exon 11 in the DNAs from 13 additional first degree rela-
tives of the affected puppy, and one unrelated unaffected
control revealed that all four affected males were hemizy-
gous for this variant and the dam of these two affected lit-
ters was a heterozygous carrier, while all the remaining dogs
carried only the wild type A allele at this position.To investigate the occurrence and potential distribu-
tion of the MTM1 c.1151A > C variant among healthy
Rottweilers, a Custom TaqMan® SNP Genotyping Assay was
developed to distinguish the two alternate alleles. Applica-
tion of this assay to the genomic DNAs of 57 Rottweilers
(30 male and 27 female) previously tested for rabies titers
through the United Kingdom’s Pet Travel Scheme [25], as
well as 19 additional Rottweilers from Australia, including
four females, 14 males, and one of uncertain gender,
revealed that all of the 107+ X chromosomes represented
by these cohorts carried only the wild type A allele.
To assess the likelihood that the non-conservative
replacement of the acidic amino acid glutamine with the
Figure 4 Ultrastructural studies of the biceps femoris muscle
from a Rottweiler puppy affected with XLMTM (puppy III-12).
Prominent features include myofibrillar disarray, SR profiles (arrows),
autophagosomes (arrowheads) and other degenerating organelles
(A), centrally located nuclei (B), dilated tubular structures (arrows,
C), and mitochondrial accumulation with interspersed glycogen
granules (D). A cross-section of a double membrane bound (arrows)
autophagic vacuole is shown with entrapment of organelles including
T-tubule (arrowhead) and junctional SR (asterisk) profiles, other
membranes of undetermined origin, mitochondria, and glycogen
granules (E). Multiple adjacent autophagic vacuoles occupying
abnormal fiber regions are shown in (F). Scale bar in lower right corner of
F = 0.2 μm for A, D and E, 0.6 μm for B, 0.3 μm for C, and 0.3 μm for F.
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pathogenic alteration in myotubularin structure and
function, we subjected this mutation to several predictive
algorithms. Residue Q384 is highly conserved and invariant
among all the known myotubularins in species ranging
from mammals to birds, fish, amphibians, and even inverte-
brates such as drosophila (Figure 5C). Canine MTM1
p.(Q384P) is predicted ‘damaging’ by SIFT (score of
0.00, with Median Sequence Conservation = 3.06 based on
146 unique sequences, where scores <0.05 are considered
damaging), ‘probably damaging’ by PolyPhen-2 (score
1.000, where >0.85 is classified probably damaging), and a
SuSPect score of 89, with disease-associated single amino
acid variants predicted to have a score above 50 [22]. In
fact, inspection of the SuSPect scores for all of the possible
amino acid substitutions for residues 370-418 reveals aregion of the protein encompassing the phosphatase active
site with particularly high scores (mean 80.3 +/- 20) versus
overall scores for the entire protein (mean 48.2 +/- 27),
suggesting that this region of the protein is particularly
sensitive to missense changes.
Molecular modeling of the MTM1 p.(Q384P) mutation
The human and canine myotubularin proteins are collinear
with no gaps with 96% identity and 98% similarity. We
used Phyre2 [23] to predict the protein structure of canine
myotubularin by homology modeling. The server gen-
erated a robust structural model based on the crystal
structure of MTMR2 using as its template RCSB Protein
Data Bank entry 1ZSQ [26]. The positive alignment
encompassed residues 33-543 of canine myotubularin
with 100% confidence based on 69% identity in the aligned
regions. Not surprisingly, given the high degree of evolu-
tionary conservation, the resulting model predicts that
canine myotubularin has essentially the same structure as
human myotubularin, with a conserved P-loop at the
enzyme’s phosphatase active site (residues 375-381) and a
conserved alpha helix (α-10) immediately distal to it
(Figure 6A) [26]. Residue Q384 is part of α-10, and is only
three amino acids distal to the P-loop (Figures 5B,C, 6A).
Examination of the region encompassing amino acids
370-394, including β-sheet 14, the P-loop, and α-10
predicts that the alpha helical structure of α-10 extends
proximally to include the last residue of the P-loop at
R381 (Figure 5B). Mutating Q384 to proline is predicted
to disrupt this alpha helix, leading to R381 adopting a
non-helical coil structure (Figure 6B, C). This is supported
by clash analysis, which predicts that the change from
glutamine to proline at position 384 leads to moderate
interference with the side chain of R381 when just
the 30 amino acids from position 369-398 are modeled
(Figure 6D,E).
Given the structurally constrained nature of the P-loop,
one might predict that this alteration should abolish, or at
least modify, the enzymatic activity at this active site.
Further support for this hypothesis comes from examin-
ation of the cognate Q384 position across the 13 most
similar myotubularin-related proteins. The glutamate is
conserved across all seven enzymatically active mem-
bers of the family, but is replaced by a cysteine in
MTMR10 and a lysine in MTMR11 and MTMR12,
representing three of the six known enzymatically inactive
myotubularins (Figure 5D).
Discussion
Here we report a second genetically proven canine
homolog of XLMTM due to mutation of the MTM1
gene. Both the previously reported Labrador retriever
mutation, MTM1 p.(N155K), and this Rottweiler mutation,
MTM1 p.(Q384P), represent missense changes replacing
Figure 5 Mutation analysis of the MTM1 gene in affected and unaffected Rottweilers. (A) DNA sequence tracings from Sanger sequencing
of a portion of MTM1 exon 11 centered on cDNA position 1151 illustrating mutation of adenine to a cytosine in a hemizygous affected puppy
(middle), compared with an unaffected male littermate (bottom) and his carrier mother (top). (B) Schematic of full-length myotubularin with
major domains and motifs showing the location of the wild type glutamine (Q) at position 384. (C, D) Alignments of a 30 amino acid stretch of
myotubularins from different species (C), and from each of the first 13 human myotubularin related proteins (D), centered about the position of
Q384. (D) The six enzymatically inactive myotubularin related proteins are separated by a space from the eight active forms. Residues constituting
the phosphatase active site (P-loop) and α helix 10 are indicated by brackets above.
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in exon 7, located in the linker region between the
PH-GRAM and the phosphatase domains and was
associated with reduced levels of myotubularin pro-
tein. Unfortunately, due to issues of cross-reactivity
(possibly with MTMR1 or MTMR2) with available anti-
bodies, we were unable to reliably evaluate myotubularin
localization or levels in the affected Rottweiler’s muscles,although western blotting suggested that myotubularin
levels were similar in affected and wild type dogs and
the staining pattern co-localized, as expected, in neck-
lace fibers with that of the RyR1 (data not shown).
Nevertheless, the p.(Q384P) mutation is predicted to
dramatically alter, and possibly abolish, phosphatase
activity so we posit that this leads to production of a
stable, but catalytically inactive protein. This exact residue
Figure 6 Structural predictions of the effects of the MTM1 p.(Q384P) mutation. Jmol visualizations of predicted structural models of
full-length canine myotubularin generated by Phyre2 (A) show the PH-GRAM domain (yellow) oriented at the top and the phosphatase domain
(light blue) below. The SET and coiled coil domains are shown in blue and purple, respectively (as in Figure 5B). The P-loop is colored green and
the position of Q384 is shown in red. The region encompassing β-sheet 14, the P-loop, and α-10 (residues 370-394), is shown in isolation for the
wild type protein (B), and for the p.(Q384P) mutation (C). Note loss of alpha helical structure at arginine 381 (indicated). Repeating the Phyre2 structural
predictions for just the 30 residue peptide including positions 369-398 and modeling space-filling atoms for positions 381 and 384 illustrates predicted
steric interference between R381 and mutated P394 (E), but not wild type Q384 (D) (arrowheads).
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XLMTM, however, missense mutations of S376 and G378
(both within the P-loop), and S387, A389, and L391
(all within the adjacent α-10 helix), have been reported. Of
13 patients in the MTM1 Leiden Open Variation database
[27] with missense mutation of one of these five residues,
10 were reported to have a severe phenotype similar to
that seen in patients with MTM1 null mutations, while
three were of unknown severity.
Although a proven canine MTM1 null mutation has
not yet been reported, it is worth noting that both the
Labrador retrievers and Rottweilers exhibited similar
severe clinical phenotypes, with onset of a generalized,
progressive, and fatal myopathy in the second to third
month of life. Breeding of the Labrador MTM1 p.(N155K)
mutation onto a Beagle genetic background (that is,
‘Labbes’) has had no discernable impact on severity of
the phenotype or natural history of the disease [28],
suggesting that clinical expression of these mutations
may be largely independent of breed.
Histopathology in the CNMs, including XLMTM, may
be similar and include excessive variability in myofiber
size with numerous hypotrophic fibers, central nuclei inmyofibers reminiscent of myotubes, and the presence of
‘necklace fibers’. The necklace fibers, which are indicative
of XLMTM, may appear as a ring of increased staining
around the periphery of H&E stained myofibers, but are
most apparent upon reaction with oxidative stains [29].
The necklaces are positive for SDH or COX (Figure 2C,
D) and stain positively for components of the triad such
as DHPR, and RyR1 (Figure 3A). These, and other abnor-
mal staining intensities using antibodies against DHPR
and RyR1, are typically found in XLMTM in the Labrador
retrievers [18] and the Rottweilers presented with similar
findings. However, a striking finding unique to the
Rottweiler dogs was the presence of intensely staining
myofibers with the autophagy markers LC3 and ubiquitin
(Figure 3B) and this correlated with the presence of
abundant autophagosomes and autophagic vacuoles upon
ultrastructural examination (Figure 4E,F).
Autophagic vacuoles are not found in normal muscle
fibers but are prominent in some muscle diseases where
there is a deficiency of lysosomal enzymes as in acid
maltase deficiency and Danon disease [30], impaired
degradation of lysosomal contents due to an increase in
lysosomal pH as in chloroquine myopathy [31], or when
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vincristine myopathy [32]. Phosphatidylinositol 3-phosphate
and phosphatidylinositol 3,5-bisphosphate, the substrates
of myotubularins, are known to play important roles in
vesicular trafficking and autophagy, and in recent years
several myotubularin related proteins have been implicated
as negative regulators of autophagy [33-37]. Although
prominent upregulation of markers of autophagy has not
yet been described as a general feature of XLMTM in
humans, recent studies on two myotubularin-deficient
mouse models have revealed significant abnormalities of
the autophagy-lysosomal pathway [38,39]. Fetalvero et al.
identified a profound increase of ubiquitin aggregates, LC3
levels, and activation of mTORC1 signaling associated with
defective autophagy. Al-Qusairi et al. have shown the
autophagic pathway is hyperactivated, however, late stages
involving fusion of autophagosomes to lysosomes are
blocked, leading to abnormal accumulations of autophago-
somes similar to those seen in the affected Rottweiler’s
muscles. Whether the particularly prominent accumula-
tions in these dogs represents a general phenomenon, or
perhaps reflects the effects of a genetic variant affecting
some autophagy-related protein or other breed-specific
finding, remains to be determined.
The clinical presentation of young dogs with either of the
autosomal forms of CNM or of XLMTM is myopathic in
nature (generalized weakness, muscle atrophy, short-strided
gait) but these general signs of muscle disease are largely
non-specific and typically cannot be used to diagnose the
specific condition. If the serum CK activity is markedly
elevated, a dystrophy rather than a congenital myopathy
would be most likely. In either case, interpretation of
muscle biopsies processed at a laboratory experienced in
the diagnosis of neuromuscular diseases is of utmost
importance as the congenital myopathies are defined by the
presence of specific anatomic changes in frozen muscle
biopsy sections [19]. Identification of an excessive variability
in myofiber size, numerous myofibers containing centrally
located nuclei resembling myotubes and the identification
of ‘necklace fibers’ in the absence of dystrophic changes
should alert the muscle pathologist to the diagnosis of
either autosomal CNM or XLMTM. Then, differences in
the ages of onset and rates of progression may provide
clinical clues to allow differentiation of XLMTM from the
known autosomal CNMs and may be used to guide the
prioritization of genetic testing. XLMTM is restricted to
males, and affected puppies present with a severe progres-
sive weakness typically beginning in the first 2 months of
life and requiring euthanasia by 4 to 5 months of age. In
contrast, both Labrador retrievers with the PTPLA muta-
tion [13] and Great Danes with BIN1 mutation [14] have
similar clinical phenotypes but tend to present at older ages
and often survive well past 1 year of age [40,41]. Thus, the
diagnosis cannot be made by physical examinationalone but requires combined clinical and histopathological
evaluations leading to selection of the proper genetic test
to confirm the etiology.
TheMTM1 p.(Q384P) mutation appears to be restricted
to this one kindred of Australian Rottweilers. Enquiries as
to the history of any similar abnormalities in the dam’s
and sire’s lines have not revealed any additional cases of
congenital myopathy. Extensive pedigrees reveal ancestors
including US, UK, German, and Swedish bred dogs. The
grand dam on the dam side of the affected litters (I-3) was
imported from Germany and has not produced any
puppies with known abnormalities. DNA testing of the
dam (II-2) of the two affected litters revealed that she was
a heterozygous carrier for the MTM1 p.(Q384P) mutation,
yet testing of her dam’s (I-3) DNA demonstrated that she
was not a carrier for the mutation. Given that the dam’s
sire (I-2) was unaffected and able to breed, it is most likely
that the MTM1 mutation arose as a de novo event, either
in the germ line of either grandparent I-2 or I-3, or in the
dam II-2 during her embryonic development. Of the litter
siblings of affected dogs, the males available for follow-up
have not shown any abnormalities. The female littermates
have either been neutered or not produced any known
offspring. Nevertheless, any remaining unneutered female
littermates in the affected litters are at 50% risk to carry
the mutation and should either be neutered, or at least
tested for the mutation. Regardless, unlike the situation
with regard to the autosomal recessive PTPLA mutation
that is distributed widely among geographically separated
Labrador retrievers [42], it is highly unlikely that this
particular MTM1 mutation would be found in other
Rottweilers, apart from direct lineal descendants of this
single kindred.
Conclusions
A progressive, non-dystrophic myopathy in male puppies
from two litters of Rottweilers born in Australia repre-
sents the second genetically confirmed instance of
XLMTM in dogs. The pathogenic mutation, MTM1 p.
(Q384P), lies three amino acids distal to the P-loop at
the phosphatase active site and likely alters its structure
through disruption of an adjacent alpha helix. Affected
puppies have a similar clinical presentation and progres-
sive course as previously reported Labrador retrievers
with MTM1 p.(N155K), suggesting that both models are
representative of a variety of MTM1 mutations as seen
in human patients. Possible or probable XLMTM in
dogs can be predicted for litters containing exclusively
affected males with a skeletal myopathy of early onset
and rapidly fatal course, together with characteristic
skeletal muscle pathological findings, and should lead to
diagnostic sequencing of the entire MTM1 gene as this
condition may be due to multiple independent mutational
events regardless of breed or geographic origin.
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